Introduction
Patients with axial spondyloarthritis (SpA) differ in the predominance of individual clinical manifestations. This phenotypic heterogeneity of the disease makes the evaluation of disease activity in axial SpA complex and prone to misrepresentation, if individual domains are used to evaluate disease activity.
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) aggregates single-item variables (fatigue, back pain, joint pain/swelling, enthesitic points, intensity and duration of morning stiffness) in a single score, and has been the most widely used measure of disease activity in axial SpA [1] . However, the BASDAI measures only part of disease activity, only includes patient reported measures, does not weight individual clinical manifestations (the variables are simply summed without taking the relative importance and dependency into account), does not take into account variable redundancy (the phenomenon that separate variables cover the same aspect of the disease and may have high correlation) and lacks specificity for inflammatory processes. Moreover, BASDAI is fully patient-oriented, and patients and physicians have different perspectives of the disease [2] . Furthermore, a modified version of the BASDAI containing no questions about peripheral arthritis and enthesitis (mini-BASDAI) has also been tested and did not perform better than the original version [3, 4] .
Therefore, a new instrument to measure disease activity in axial SpA was required. This new instrument should be truthful, discriminative and feasible, and should include domains/items that are considered relevant by both patients and physicians.
The literature between January 2009 and January 2011 was searched for new measurement instruments for clinical disease activity in axial SpA. Only articles about the Ankylosing Spondylitis Disease Activity Score (ASDAS) were found and therefore this review will only focus on this new assessment tool. new composite measure for disease activity in axial SpA. The first step in developing this new tool was a Delphi process among ASAS members through which domains and variables describing disease activity in axial SpA were identified (Table 1) , followed by a meeting to resolve outstanding problems. This process ensured content validity. The items selected in the Delphi exercise were then further tested in International Study of Starting anti-TNF agents in AS (ISSAS) [5] , a large international database of ankylosing spondylitis (AS) patients, in which rheumatologists determined which patients in their opinion should start a TNF-blocker after a regular clinical visit. Principal component analysis with the 11 principal components shown in Table 1 was performed [the Bath AS Functional Index (BASFI) was excluded], followed by discriminant function analysis on factor loadings to determine the best composition of factors [6 ] . This methodology ensured face and construct validity.
On the basis of these analyses, the following five variables were selected and combined in one formula: back pain (BASDAI question 2), duration of morning stiffness (BASDAI question 6), patient global assessment, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Three alternative formulas were derived to meet criticism about the feasibility of including two acute phase reactants simultaneously and about the duplicity of including patient global assessment and other patient reported outcomes in the same formula. Therefore, in the alternative formulas, ESR (or CRP) was replaced by peripheral pain/swelling (BASDAI question 3) and patient global was replaced by fatigue (BASDAI question 1).
The four formula options were tested in ISSAS (from which they were developed) and Outcome in AS International Study (OASIS) as an independent dataset [7] , and standardized mean differences (a value that quantifies the number of standard deviations by which two groups differ) were calculated ( Table 2 ) [6 ] . In ISSAS, the discriminator was the rheumatologists' judgement that a patient required a TNF-blocking drug (yes vs. no) and in OASIS, the discriminator was patient and physician global assessment of disease activity at baseline (high vs. low) [6 ] . Results showed that all four ASDAS formulas performed similarly and better than the BASDAI and single-item variables ( Table 2) .
Further validations were carried out in the Norwegian DMARD (NOR-DMARD) [9] registry and in data from four randomized clinical trials (RCTs) in AS using TNF-blockers ( Table 2 ) [8 ] . In NOR-DMARD, the following discriminators were used: physician global assessment at baseline and after 6 months (high vs. low), patient in acceptable symptom state (PASS) after 6 months (yes vs. no), patients considering themselves considerably improved after 3 months (yes vs. no) and impact of treatment after 3 or 6 months (TNF-blocker vs. DMARD). In the RCTs-merged population, discrimination between patients treated with TNF-blockers and placebo and sensitivity to change (using Guyatt's effect size) were tested [8 ] . Again the four ASDAS formulas performed very well: they were highly discriminatory in differentiating patients with different levels of disease activity and in differentiating those with different levels of change. Notably, the ASDAS performed better than the BASDAI and single-item variables in all settings: patient-based or physician-based, reflecting status or change, normal or raised CRP levels and in the presence or absence of peripheral arthritis ( Table 2 ).
In summary, at this point, a weighted and highly discriminative continuous disease activity index for axial SpA based on items obtained by consensus had been statistically constructed and validated [6 ,8 ] . On the basis of feasibility, the ASAS membership selected the ASDAS containing CRP as acute phase reactant as 340 Spondyloarthropathies
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The evaluation of disease activity in axial spondyloarthritis (SpA) is complex and multifactorial. Currently used single variable parameters and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) only cover a part of the construct of disease activity. The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new disease activity index that maximizes the available information.
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the preferred version and the one with ESR as the alternative version (Table 3 ).
Ankylosing Spondylitis Disease Activity Score cut-offs
The next step to consolidate the ASDAS as an instrument to measure disease activity in AS was the development of cut-offs for 'disease activity states' and 'improvement scores' ('response levels').
'Disease activity states' are defined as measurable, crosssectional levels of disease activity. They are important for supporting decisions about entry into clinical trials, for supporting treatment changes and for defining therapeutic goals. 'Response levels' are defined as change scores in a continuous variable (with cut-points for each response level). They help to determine whether treatments really work, that is, whether they actually produce clinically important improvement, allowing investigators, clinicians, regulators and patients to determine the efficacy (or lack thereof) of a given intervention and to communicate about response using the same metric.
To define the cut-offs, receiver operating characteristic (ROC) analysis against several external criteria was performed, using data from the NOR-DMARD registry [11 ] . ASAS members debated and voted to define four disease activity states: inactive disease, moderate disease activity, high disease activity, and very high disease activity. In the ROC analysis, both the patient and physician global assessments at predefined levels (<1, <3 and >6 on a 0-10 point scale) were used as external constructs for 'inactive disease', to separate 'moderate' from 'high disease activity' and for 'very high disease activity', respectively. Additionally, for determining the cut-off for 'inactive disease' ASAS partial remission criteria were also used as an external anchor. Several approaches were used to determine the optimal cut-off and the final choice was made on clinical and statistical grounds. Based on the results, the following cut-offs were selected: ASDAS less than 1.3 to define 'inactive disease', ASDAS greater or equal to 1.3 and less than 2.1 to define 'moderate disease activity', ASDAS greater or equal to 2.1 and less than or equal to 3.5 to define 'high disease activity', and ASDAS greater than 3.5 to define 'very high disease activity' (Fig. 1a ).
Regarding improvement scores, the external criterion that was used for the ROC analysis was a 'global rating of change', available in NOR-DMARD. This is a Likerttype scale scored for health change by the patient, according to five categories: 'much better', 'better', 'unchanged', 'worse' and 'much worse'. Selected cut-offs for improvement scores were a change of at least 1.1 units for 'clinically important improvement' (defined by using the patient's report of being 'better' or 'much better' since the start of treatment as an external criterion) and a change Fig. 1 of [11 ] . Table 3 The two Ankylosing Spondylitis Disease Activity Score formulas: Ankylosing Spondylitis Disease Activity Score-C-reactive protein (preferred) and Ankylosing Spondylitis Disease Activity Score-erythrocyte sedimentation rate (alternative) of at least 2.0 units for major improvement (defined by using the patient's report of being 'much better' since the start of treatment as an external criterion) (Fig. 1b) .
ASDAS
The above-defined cut-offs were then cross-validated in NOR-DMARD at different time-points and in AS Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT), a database of AS patients participating in a RCT with a TNF-blocker. Results showed a clear shift of treated patients from higher towards lower disease activity states. Moreover, the comparison between the active and placebo groups in the RCT population showed that ASDAS improvement scores were more discriminative than classical improvement criteria (ASAS20, ASAS40, BASDAI50 and DBASDAI of at least 2 units) and also that ASDAS inactive disease was more discriminative than ASAS partial remission criteria ( Table 4 ).
The cross-validation process was performed taking into account the aspects of truth and discrimination of the OMERACT filter and in May 2010, the results were presented and discussed in the OMERACT community. The proposed cut-offs, which are applicable both to ASDAS-CRP and ASDAS-ESR (although the two ASDAS scores are not interchangeable), were scrutinized and obtained the endorsement of this international group of people with a broad background including clinicians, researchers and patients [10] .
Further validation of the Ankylosing Spondylitis Disease Activity Score
The construct validity and responsiveness of the ASDAS have been assessed in several recent studies. In a Danish cohort of patients with axial SpA treated with TNFblockers (BIOSPA), Pedersen et al. [12] showed that ASDAS-CRP had the highest responsiveness (higher effect size and standardized response mean) compared with various conventional clinical measures, namely the BASDAI, single-item patient reported outcomes, physician global, CRP, spinal mobility and enthesitis scores, MRI lumbar spine and sacroiliac joints inflammation scores, MRI sacroiliac joints chronicity score and tender/swollen joint counts. This study also confirmed that the ASDAS had a more balanced correlation with patient and physician global assessments than BASDAI, which is only driven by patient reported measures. Interestingly, in this study, ASDAS changes not only correlated significantly with changes in other measures of disease activity [such as BASDAI (rho ¼ 0.76) and CRP (rho ¼ 0.79)], but also correlated with changes in MRI inflammation scores at the sacroiliac joints (rho ¼ 0.46) or sacroiliac joints plus lumbar spine (rho ¼ 0.34), contrary to BASDAI and CRP, in which the correlation with changes in MRI inflammation scores was not statistically significant. In a Turkish study [13] , the ASDAS-CRP and ASDAS-ESR also performed better than patient-reported measures (including BASDAI) and acute-phase reactants, discriminating better between high and low disease activity status, and performance was not affected by the presence of peripheral arthritis. In another Turkish cohort of patients with AS, Aydin et al. [14] showed that all ASDAS formulas correlated well with physician global, patient-reported outcomes and acute phase reactants, and performed well in discriminating between patients requiring TNF-blockers or not, and between patients with high vs. low disease activity according to physician's assessment. In a Canadian population of patients with axial psoriatic arthritis, Eder et al. [15] reported that the ASDAS-CRP and ASDAS-ESR correlated well with patient and physician global, and showed good discriminative ability between high and low disease activity states (according to patients, physician and treatment decisions). However, in both these two last studies [14, 15] , BASDAI performance was very similar to (but not better than) the ASDAS. Recently, it was also reported that ASDAS-CRP performed well in patients with AS treated with TNF-blockers over 8 years [16] and in patients with active nonradiographic axial SpA treated with adalimumab and retreated after interruption of Measuring disease activity in axial SpA Machado and van der Heijde 343 therapy and flare [17] . Furthermore, in a comparative analysis of the performance of various efficacy measurements in AS, using data from the AS Study Comparing Enbrel with Sulphasalazine Dosed Weekly (ASCEND) trial [18] , the ASDAS-CRP again showed the best discriminatory capacity, followed by the objective measure CRP. Overall subjective outcome measures, such as nocturnal back pain, back pain, physician global assessment of disease activity and BASDAI, showed somewhat lower discriminatory capacity than ASDAS (or CRP alone) [18] . Of note, it has also been reported that high sensitivity CRP testing increases the sensitivity and responsiveness of ASDAS-CRP [11 ,19] . In the past, it had already been noted that high sensitivity CRP could be superior to standard CRP in assessing disease activity in axial SpA [20] .
The ASDAS cut-off for 'inactive disease' (a remissionlike state) may be an important guideline for achieving a therapeutic aim. Compared with ASAS partial remission criteria, ASDAS inactive disease has the advantage of being independent of BASFI: patients with a lot of structural damage who (as a consequence) have a high BASFI may never achieve ASAS partial remission, whereas they may more easily achieve inactive disease.
In the ASDAS cut-offs validation study [11 ] , more patients achieved the inactive disease state compared with ASAS partial remission while retaining higher discriminatory capacity between treatment groups (Table 4 ). Similar results were found in an independent cohort (ATLAS -Adalimumab Trial evaluating Longterm efficacy and safety for AS), in which potential causes of observed differences in response rates were investigated over a 5-year period [21] . This study showed that patients who achieved ASDAS inactive disease but not ASAS partial remission had higher baseline BASFI and modified Stoke AS Spine Score (mSASSS) values, compared with those who achieved both disease activity states' definitions. BASFI was the most frequently observed ASAS component to have not met the required value of less than 2 (range 0-10) in the subgroup achieving ASDAS inactive disease but not ASAS partial remission. Even higher baseline BASFI and mSASSS values were noted for those who did not fulfil either criterion. These observations confirmed that ASDAS inactive disease detects more patients in a remission-like state and allows better differentiation between active treatment and placebo. This is likely because of the inclusion of BASFI in ASAS partial remission, which may not reflect response to effective therapies if irreversible damage and functional disability are present [21] .
Truth, discrimination and feasibility
In summary, the ASDAS is an index that maximizes the available information (the signal) and reduces the random error associated with measurement (the noise). It performs well methodologically and has high face, content and construct validity, in both clinical practice and research settings. Moreover, it is a highly discriminatory instrument for assessing disease activity in axial SpA. ASDAS good performance as a continuous measure and as a state/response measure was shown in various international datasets, including RCTs and observational cohorts.
Feasibility is another important aspect for the success of an outcome measure [22] . Although the ASDAS includes logarithmic (CRP) or root (ESR) transformed factors, the feasibility of such formulae has already been proven by the wide use and successful implementation of the Disease Activity Score (DAS) in rheumatoid arthritis, both for research and clinical practice. This has largely been promoted by the disseminated use of online and hand-held calculators. The ASDAS-CRP and ASDAS-ESR formulas are actively being incorporated in handheld calculators and an ASDAS online calculator is already available at the ASAS website (www.asas-group. org). A quick ASDAS calculator paper-form with tables for quick arithmetic conversion of ASDAS items is also available at the website, as an alternative method to electronic devices. Moreover, it should be noted that the ASDAS is less time-consuming than the DAS because it does not involve joint counts. Therefore, ASDAS seems to be a feasible and practical tool that could easily be adopted by clinicians.
Conclusion
A new disease activity index in axial SpA has been developed. The ASDAS and its cut-off values may help clinicians to better assess patients with axial SpA, more reliably determine their disease activity status, the effectiveness of treatments and whether they are providing clinically meaningful improvement. The higher discriminatory capacity and sensitivity to change of the ASDAS may have important implications in reducing the sample size calculation for clinical trials. The use of the ASDAS as the primary outcome in a trial with a TNF-blocker reduces the number of required patients by about 40% in comparison to the use of the BASDAI while maintaining similar power. The ASDAS will also allow clinicians, investigators, regulators and patients to continue communicating about treatment response using the same metric and will facilitate studying the impact of disease activity states on prognosis.
